
zzso low molecular weight zzso and zzso have zzso activity in zzso and in animal zzso We studied the safety and efficacy of the combination of these drugs in patients with advanced zzso In all, 50 patients were zzso zzso was given orally at a dose of 50 zzso zzso zzso zzso was administered as a daily subcutaneous injection of 200 units zzso for the first 28 days and zzso units zzso zzso was given at 10 zzso zzso zzso zzso plasma and urinary zzso factors were measured at baseline and after 1 month of zzso zzso of release of zzso necrosis factor alpha zzso from peripheral zzso was used as a surrogate zzso end zzso There was one case of zzso stroke and one upper gastrointestinal zzso The zzso toxicity was zzso One of 10 patients with zzso cancer had a partial response, and three patients had a prolonged period of stable zzso The treatment significantly inhibited zzso zzso zzso release from patient's zzso The combination of zzso zzso and zzso is well tolerated and has in zzso zzso zzso of zzso zzso release from zzso is a surrogate zzso marker of zzso zzso 

